Maze Therapeutics Ownership | Who Owns Maze Therapeutics?


OverviewForecastFinancialsChart

Maze Therapeutics Ownership Summary


Maze Therapeutics is owned by 25.04% institutional investors, 1.46% insiders, and 73.50% retail investors. Frazier life sciences management is the largest institutional shareholder, holding 10.63% of MAZE shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.34% of its assets in Maze Therapeutics shares.

MAZE Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockMaze Therapeutics25.04%1.46%73.50%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Frazier life sciences management4.57M10.63%$136.33M
Trv gp iv4.47M10.41%$133.55M
Arch venture management4.12M9.59%$122.98M
Deep track capital, lp3.48M8.09%$103.81M
Janus henderson group2.86M6.65%$85.28M
Paradigm biocapital advisors lp2.74M6.39%$81.92M
Blackrock funding, inc. /de2.57M5.98%$76.73M
Ah capital management1.70M3.96%$50.81M
Vr adviser1.60M3.73%$47.82M
Vanguard group1.70M3.71%$70.31M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Trv gp iv4.47M50.04%$133.55M
Arch venture management4.12M18.16%$122.98M
General catalyst group management1.04M16.85%$30.92M
Trv gp v950.80K7.08%$28.38M
Washington university280.80K5.23%$8.38M
Ah capital management1.70M3.94%$50.81M
Frazier life sciences management4.57M3.51%$136.33M
Foresite capital management iv156.90K1.98%$4.68M
Logos global management lp1.24M1.84%$36.86M
Vr adviser1.60M1.78%$47.82M

Top Buyers

HolderShares% AssetsChange
Paradigm biocapital advisors lp2.74M1.67%2.74M
Adage capital partners gp1.18M0.05%1.18M
Cormorant asset management, lp750.00K1.12%750.00K
Farallon capital management373.00K0.06%373.00K
Vanguard group1.70M0.00%362.06K

Top Sellers

HolderShares% AssetsChange
Bellevue group---887.71K
Deep track capital, lp3.48M1.70%-768.88K
Marshall wace, llp310.64K0.01%-536.83K
Matrix capital management company, lp---480.00K
Woodline partners lp650.23K0.07%-385.00K

New Positions

HolderShares% AssetsChangeValue
Paradigm biocapital advisors lp2.74M1.67%2.74M$81.92M
Adage capital partners gp1.18M0.05%1.18M$35.16M
Cormorant asset management, lp750.00K1.12%750.00K$22.39M
Farallon capital management373.00K0.06%373.00K$11.13M
Candriam s.c.a.278.17K0.04%278.17K$8.30M

Sold Out

HolderChange
Daiwa securities group-160.00
Srs capital advisors-307.00
Comerica bank-636.00
Amalgamated bank-674.00
Corebridge financial-4.33K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202657-60.42%10,759,374-77.75%250.22%36-65.71%9-55.00%
Dec 31, 202575-20.21%24,665,288-42.60%530.56%57-8.06%9-40.00%
Sep 30, 202549-33.78%17,110,255-55.94%390.50%34-19.05%7-46.15%
Jun 30, 20257415.63%38,836,4378.98%880.57%42-34.38%13-
Mar 31, 202567-40,037,113-139-67---

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv1.16M2.34%-
iShares Russell 2000 ETF619.13K1.24%5.22K
Janus Henderson Hrzn Biotec E2 USD514.40K1.03%-
Eventide Healthcare & Life Sciences I324.04K0.65%324.04K
Fidelity Select Biotechnology311.88K0.63%-
Vanguard Institutional Extnd Mkt Idx Tr239.07K0.48%3.98K
iShares Biotechnology ETF231.58K0.47%37.77K
Fidelity Small Cap Index209.91K0.42%1.99K
iShares Russell 2000 Value ETF208.74K0.42%1.13K
BlackRock Health Sciences Opps Inv A184.45K0.37%-

Recent Insider Transactions


DateNameRoleActivityValue
May 22, 2026Coloma Jason V Chief Executive OfficerSell$64.43K
May 22, 2026Coloma Jason V Chief Executive OfficerSell$117.10K
May 26, 2026Coloma Jason V Chief Executive OfficerSell$665.52K
May 15, 2026Coloma Jason V Chief Executive OfficerSell$3.02K
May 15, 2026Coloma Jason V Chief Executive OfficerSell$47.37K

Insider Transactions Trends


DateBuySell
2026 Q2-12
2026 Q1-25
2025 Q4-8
2025 Q3-1

MAZE Ownership FAQ


Who Owns Maze Therapeutics?

Maze Therapeutics shareholders are primarily institutional investors at 25.04%, followed by 1.46% insiders and 73.50% retail investors. The average institutional ownership in Maze Therapeutics's industry, Biotech Stocks , is 35.75%, which Maze Therapeutics falls below.

Who owns the most shares of Maze Therapeutics?

Maze Therapeutics’s largest shareholders are Frazier life sciences management (4.57M shares, 10.63%), Trv gp iv (4.47M shares, 10.41%), and Arch venture management (4.12M shares, 9.59%). Together, they hold 30.62% of Maze Therapeutics’s total shares outstanding.

Does Blackrock own Maze Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Maze Therapeutics.

Who is Maze Therapeutics’s biggest shareholder by percentage of total assets invested?

Trv gp iv is Maze Therapeutics’s biggest shareholder by percentage of total assets invested, with 50.04% of its assets in 4.47M Maze Therapeutics shares, valued at 133.55M$.

Who is the top mutual fund holder of Maze Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Maze Therapeutics shares, with 2.34% of its total shares outstanding invested in 1.16M Maze Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools